browser Warning Icon You are using an older version of Internet Explorer. You are viewing this site with limited functionalities.
Making the Case for the S&P Biotechnology Select Industry Index How does it affect a portfolio when this high-risk/high-reward industry is included?
BY Tianyin Cheng

Biotechnology has famously improved our quality of life for decades. It addresses many global health problems, such as infectious and age-related diseases. Investors can see the potential for significant gains in this sector, due to its potential for new sources of return and diversification of risk. However, this also comes with the possibility of losses. The S&P Biotechnology Select Industry Index’s “basket” approach to allocation may provide a solution for those concerned with risk. It aims to provide diverse exposure to listed biotechnology (biotech) companies across large-, mid-, small-, and micro-cap companies in the U.S.


Based in genetic analysis and engineering, biotech firms primarily engage in the research, development, manufacturing, and, to a lesser extent, marketing of healthcare products based on genetic analysis and engineering. Biotech has a few important industry-specific characteristics.

Download Full Article (388K)

Sign up for email updates

Get our latest insight on the markets.

Thank you for subscribing!